Institute of Immunology, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
Sci Rep. 2022 Aug 29;12(1):14666. doi: 10.1038/s41598-022-18865-7.
Experimental and clinical studies have shown that the sympathetic nervous system (SNS) stimulates cancer progression and reduces the efficacy of oncological treatment. These effects may be reduced by pharmacological and psychotherapeutical approaches attenuating SNS tone. Therefore, it is necessary to identify those cancer survivors whose sympathetic modulation is excessively increased. For determination of SNS modulation, non-invasive method of heart rate variability (HRV) is widely used. In our study, HRV was determined from 5-min heartbeat recordings in healthy volunteers and in women with benign or malignant breast neoplasias, both in newly diagnosed patients and in women after initial treatment. We showed impaired cardio-vagal regulation in breast cancer patients (linear methods) and also found the increased sympathetic modulation indicated by the non-linear (the symbolic dynamics 0V%) parameter. This non-linear HRV analysis seems to be more sensitive than the linear one, indicating significant differences also in survivors after initial therapy in comparison to healthy controls. The lower sample entropy revealed reduced complexity in heart rate control in both breast cancer survivors groups. These findings suggest that HRV detection represents an inexpensive, easy, and reliable method for identification of those patients with breast cancer whose sympathetic modulation is significantly increased and in which the interventions, aimed at normalizing the balance in the autonomic nervous system (e.g. psychotherapy, biofeedback, treatment by β-blockers) may be the most effective.
实验和临床研究表明,交感神经系统(SNS)会刺激癌症进展,降低肿瘤治疗的疗效。通过药物和心理治疗方法来减弱 SNS 张力,可以减轻这些影响。因此,有必要确定那些交感神经调节过度增加的癌症幸存者。为了确定 SNS 的调节,广泛使用心率变异性(HRV)的非侵入性方法。在我们的研究中,从健康志愿者和新诊断的良性或恶性乳腺肿瘤女性的 5 分钟心跳记录中确定了 HRV,包括初始治疗后的女性。我们发现乳腺癌患者的心脏迷走神经调节受损(线性方法),并且还发现了由非线性(符号动力学 0V%)参数表示的交感神经调节增加。这种非线性 HRV 分析似乎比线性分析更敏感,表明与健康对照组相比,初始治疗后的幸存者也存在显著差异。较低的样本熵表明,两组乳腺癌幸存者的心率控制复杂性降低。这些发现表明,HRV 检测代表了一种廉价、简单、可靠的方法,可以识别那些交感神经调节明显增加的乳腺癌患者,并且针对自主神经系统(例如心理治疗、生物反馈、β受体阻滞剂治疗)的干预措施可能是最有效的。